sur SynBiotic SE (isin : DE000A3E5A59)
SYNBIOTIC Announces Strategic Expansion and Investments for 2025
In 2024, SYNBIOTIC SE, a key player in Europe's industrial hemp and cannabis sector, executed four major investments. These include companies like Ilesol Pharmaceuticals and WEECO Pharma, aimed at consolidating their market position. SYNBIOTIC plans more acquisitions in 2025, targeting value chain enhancement from cultivation to retail, thus bolstering sales and profits.
Germany's cannabis legalisation in 2024 marked a significant industry shift. Despite political instability post-legalisation, SYNBIOTIC remains optimistic about regulatory changes boosting industrial hemp growth. The removal of the "intoxication clause" could simplify operations, driving the sector's expansion further.
The company's strategy focuses on innovation, efficient supply chains, and strategic expansion to ensure sustainable industry growth. SYNBIOTIC's management assures investors of robust preparation for future opportunities.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SynBiotic SE